Please check them out and share these important opportunities with other members
of the angiosarcoma community!
Dr. Antonescu has drafted a budget based on a large scale genomic analysis
of angiosarcoma tumors.
Not exact matches
However, when the researchers switched on KRAS in the preclinical models, an entirely different kind
of tumor formed, called
angiosarcoma.
Dr. Klauber - DeMore's lab was the first to discover that
angiosarcoma cells produce an excess
of SFRP2.
In a paper published by PLOS - ONE, UNC Lineberger Comprehensive Cancer Center members Nancy Klauber - DeMore, MD, professor
of surgery, and Paul Dayton, PhD, professor
of biomedical engineering, were able to visualize lesions created by
angiosarcoma, a malignant cancer that develops on the walls
of blood vessels.
The fact that she has found them to be differentially regulated in
angiosarcoma tumors has led to the hypothesis that there are epigenetic regulators
of these genes that have yet to be identified through the genomic profiling applied to these studies thus far.
Many people with
angiosarcoma, a rare and aggressive cancer
of the blood vessel lining, survived for only about six months beyond diagnosis.
Because
angiosarcoma is an exceedingly rare cancer, it has never been the focus
of large scale scientific endeavors.
The goal
of this project is to generate the largest database
of genomic and clinical information about
angiosarcoma and share it with the entire biomedical community in order to rapidly facilitate discoveries.
Yet despite killing 40,000 women and men every year — a number that has not budged in decades despite gains in detection and treatment
of early breast cancers — MBC shares something in common with the much rarer
angiosarcoma: Medical researchers know surprisingly little about it.
A total
of 48 patients were included in the analysis, across six cohorts: liposarcoma (6 patients), vascular sarcomas including
angiosarcoma and leiomyosarcoma (10 patients), undifferentiated pleomorphic sarcoma (5 patients), synovial sarcomas (5 patients), osteosarcomas (5 patients), and other sarcoma subtypes (17 patients).
The combination
of durvalumab and tremelimumab offered a modest response rate in unselected patients with heavily pretreated metastatic sarcoma, but higher rates were seen in specific subtypes, including
angiosarcoma and alveolar soft - part sarcoma (ASPS).
Therefore, identifying these genes also advances scientists» understanding
of common human cancers such as lymphoma, and rare
angiosarcomas.
Equivalents
of both lymphoma and
angiosarcoma occur spontaneously in pet dogs.
Twenty percent
of golden retrievers develop hemangiosarcoma [5], which is clinically and histologically similar to human visceral
angiosarcoma [10, 11].